Zydus Lifesciences Ltd. has introduced ‘Zyrifa’, a biosimilar version of Denosumab 120 mg SC, aimed at reducing and delaying serious skeletal-related events in cancer patients.
Denosumab is a monoclonal antibody with multiple bone-health indications, primarily used in treating osteoporosis and preventing skeletal complications arising when cancer spreads to the bones. This therapy will provide access and treatment for patients with bone metastases caused by breast, prostate, lung, myeloma, kidney, thyroid, head-and-neck and other solid tumours.
Bone metastases are a serious complication of advanced cancer, significantly affecting patient quality of life due to pain, fractures, spinal cord compression, reduced mobility and loss of independence. These complications most commonly affect the axial skeleton — such as the spine, pelvis and ribs — leading to severe health impacts.
‘Zyrifa’ has been launched with a maximum retail price of ₹12,495, a move that underscores Zydus’s focus on enhancing affordability and access to critical medicines for cancer patients. By offering this biosimilar, the company aims to help patients retain mobility and dignity as they undergo treatment.
Population-scale data show that bone involvement in advanced cancer is high — affecting 50–70 % of patients with advanced breast or prostate cancers and 15–40 % of those with lung, kidney, thyroid and melanoma cases over time. Addressing these skeletal complications early is crucial for maintaining patient quality of life.
This launch expands Zydus’s growing portfolio of biosimilars for cancer care, which includes treatments targeting breast cancer, prostate cancer, other solid tumours and blood cancers.
